Please upgrade your browser.
Phase III clinical trial results show promise.
These results suggest that a targeted, antiangiogenic, oncolytic adenovirus might be a valuable agent for testing in kidney cancer patients.
If you have renal cell carcinoma and have received no prior systemic therapy (interleukin-2, interferon-alpha, chemotherapy, bevacizumab, mTOR inhibitor, sunitinib, sorafenib or other VEGF TKI), you may qualify for this study. Please see http://www.centerwatch.com/clinical-trials/listings/studylist.aspx?CatID=363.
What Republicans seemed to find even more infuriating was language allowing for the use of "reconciliation," a parliamentary procedure that would enable Democrats to enact health care legislation in the Senate with 51 votes, rather than the 60 necessary for overcoming a filibuster.
The award was presented on May 8, 2009 at the EU-KCA Symposium (Fourth European International Kidney Cancer Symposium, in Berlin, Germany.
The myth is that like magic, preventive medicine will simultaneously reduce costs and improve health.
Dr. Brian Day discusses Canada's failed system of socialized medicine and how to fix it in this YouTube video.
Right or wrong, more doctors will close their practices to new patients, especially patients carrying lower paying insurance such as Medicaid.
As a practicing oncologist, I am forced to give patients older, cheaper medicines. The real cost of this penny-pinching is premature death for thousands of patients.
|Powered by NeonCRM|